NPI: 1962485581 · EXETER, NH 03833 · Cytopathology Physician · NPI assigned 11/29/2005
Authorized official GRATTENDICK, MICHAEL controls 13+ related entities in our dataset. Read more
| Authorized Official | GRATTENDICK, MICHAEL (VICE PRESIDENT) |
| NPI Enumeration Date | 11/29/2005 |
Other providers sharing the same authorized official: GRATTENDICK, MICHAEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| LABORATORY MEDICINE CONSULTANTS LTD | LAS VEGAS | NV | $9.16M |
| PATHOLOGY SOLUTIONS LLC | EATONTOWN | NJ | $5.39M |
| LABORATORY OF DERMATOPATHOLOGY ADX, LLC | WOODBURY | NY | $3.57M |
| CASCADE PATHOLOGY SERVICES, CORP | PORTLAND | OR | $2.52M |
| LABORATORY MEDICINE CONSULTANTS LTD | LAS VEGAS | NV | $2.33M |
| CONSULTANTS IN LABORATORY MEDICINE OF GREATER TOLEDO | TOLEDO | OH | $2.28M |
| GREENSBORO PATHOLOGY, LLC | GREENSBORO | NC | $2.16M |
| MARK AND KAMBOUR MD PA | MIAMI LAKES | FL | $776K |
| DERMPATH NEW ENGLAND, LLC | BOSTON | MA | $643K |
| WESTERN PATHOLOGY CONSULTANTS, LTD | RENO | NV | $554K |
| HALLMARK PATHOLOGY, P.C. | MELROSE | MA | $118K |
| RICHARD BERNERT, LLC | SCOTTSDALE | AZ | $23K |
| MID-ATLANTIC PATHOLOGY SERVICES, INC. | STERLING | VA | $13K |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,876 | $48K |
| 2019 | 2,129 | $60K |
| 2020 | 1,393 | $41K |
| 2021 | 1,561 | $44K |
| 2022 | 1,869 | $56K |
| 2023 | 4,647 | $129K |
| 2024 | 487 | $14K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3,945 | 3,939 | $114K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 3,929 | 3,925 | $89K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2,762 | 2,639 | $76K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,336 | 1,335 | $41K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,325 | 1,324 | $40K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 279 | 260 | $16K |
| 88312 | 215 | 214 | $12K | |
| 88142 | 85 | 85 | $1K | |
| 88304 | 37 | 36 | $1K | |
| 88342 | 12 | 12 | $363.62 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 13 | 13 | $288.09 |
| 87510 | 12 | 12 | $182.90 | |
| 87480 | 12 | 12 | $182.90 |